Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1708 ARTÍCULOS , VIENDO DEL 1561 AL 1575

Validity of a Novel Touch Screen Tablet-Based Assessment for Mild Cognitive Impairment and Probable AD in Older Adults

Huang YP, Singh A, Chen S, Sun FJ, Huang CR, Liu SI.

Assessment. 2019 Dec;26(8):1540-1553. doi: 10.1177/1073191117748395. Epub 2017 Dec 18.

Evaluation of dietary and lifestyle changes as modifiers of S100β levels in Alzheimer's disease

D'Cunha NM, McKune AJ, Panagiotakos DB, Georgousopoulou EN, Thomas J, Mellor DD, Naumovski N.

Nutr Neurosci. 2019 Jan;22(1):1-18. doi: 10.1080/1028415X.2017.1349032. Epub 2017 Jul 11.

Motoric cognitive risk syndrome and predictors of transition to dementia: A multicenter study

Verghese J, Wang C, Bennett DA, Lipton RB, Katz MJ, Ayers E.

Alzheimers Dement. 2019 Jul;15(7):870-877. doi: 10.1016/j.jalz.2019.03.011. Epub 2019 Jun 1.

A circuit view of deep brain stimulation in Alzheimer's disease and the possible mechanisms

Yu D, Yan H, Zhou J, Yang X, Lu Y, Han Y.

Mol Neurodegener. 2019 Aug 8;14(1):33. doi: 10.1186/s13024-019-0334-4.

Meta-Analysis of Gene Expression Changes in the Blood of Patients with Mild Cognitive Impairment and Alzheimer's Disease Dementia

Bottero V, Potashkin JA.

Int J Mol Sci. 2019 Oct 30;20(21):5403. doi: 10.3390/ijms20215403.

Factors Associated with Alzheimer's Disease: An Overview of Reviews

Rochoy M, Rivas V, Chazard E, Decarpentry E, Saudemont G, Hazard PA, Puisieux F, Gautier S, Bordet R.

J Prev Alzheimers Dis. 2019;6(2):121-134. doi: 10.14283/jpad.2019.7.

Antioxidant Properties of Crocus Sativus L. and Its Constituents and Relevance to Neurodegenerative Diseases; Focus on Alzheimer's and Parkinson's Disease

Hatziagapiou K, Kakouri E, Lambrou GI, Bethanis K, Tarantilis PA.

Curr Neuropharmacol. 2019;17(4):377-402. doi: 10.2174/1570159X16666180321095705.

Mass spectrometry: A platform for biomarker discovery and validation for Alzheimer's and Parkinson's diseases

Cilento EM, Jin L, Stewart T, Shi M, Sheng L, Zhang J.

J Neurochem. 2019 Nov;151(4):397-416. doi: 10.1111/jnc.14635. Epub 2019 Jan 31.

Neuroprotective Actions of Glucagon-Like Peptide-1 (GLP-1) Analogues in Alzheimer's and Parkinson's Diseases

Batista AF, Bodart-Santos V, De Felice FG, Ferreira ST.

CNS Drugs. 2019 Mar;33(3):209-223. doi: 10.1007/s40263-018-0593-6.

Pimavanserin in Alzheimer's Disease Psychosis: Efficacy in Patients with More Pronounced Psychotic Symptoms

Ballard C, Youakim JM, Coate B, Stankovic S.

J Prev Alzheimers Dis. 2019;6(1):27-33. doi: 10.14283/jpad.2018.30.

Mitochondria, OxPhos, and neurodegeneration: cells are not just running out of gas

Area-Gomez E, Guardia-Laguarta C, Schon EA, Przedborski S.

J Clin Invest. 2019 Jan 2;129(1):34-45. doi: 10.1172/JCI120848. Epub 2019 Jan 2.

Emerging pathways to neurodegeneration: Dissecting the critical molecular mechanisms in Alzheimer's disease, Parkinson's disease

Tan SH, Karri V, Tay NWR, Chang KH, Ah HY, Ng PQ, Ho HS, Keh HW, Candasamy M.

Biomed Pharmacother. 2019 Mar;111:765-777. doi: 10.1016/j.biopha.2018.12.101. Epub 2019 Jan 3.

Therapeutic Approaches to Alzheimer's Disease Through Modulation of NRF2

Bahn G, Jo DG.

Neuromolecular Med. 2019 Mar;21(1):1-11. doi: 10.1007/s12017-018-08523-5. Epub 2019 Jan 7.

Editorial: We may need large trials to find treatments for neurodegenerative diseases

Schoenfeld DA, Benatar M.

Clin Trials. 2019 Apr;16(2):120-121. doi: 10.1177/1740774518820814. Epub 2019 Jan 10.

Cerebrospinal Fluid Concentrations of the Synaptic Marker Neurogranin in Neuro-HIV and Other Neurological Disorders

Yilmaz A, Fuchs D, Price RW, Spudich S, Blennow K, Zetterberg H, Gisslén M.

Curr HIV/AIDS Rep. 2019 Feb;16(1):76-81. doi: 10.1007/s11904-019-00420-1.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias